Semaglutide reduces risk of kidney disease deaths by > 20% (Bloomberg)

Hey folks — as clinic director, this is the kind of study that makes my week.

Published in the New England Journal of Medicine: Semaglutide significantly reduces the risk of death in patients with diabetic kidney disease. This is a big deal — kidney disease affects a huge share of people with diabetes, and until now the options for changing its course were limited.

The key numbers from the trial:

• Patients on Semaglutide were about one-fifth less likely to die from any cause than those on placebo

• Risk of serious kidney AND heart outcomes dropped by 24%

• Researchers are now talking about Semaglutide as a treatment for what's called cardio-kidney-metabolic syndrome — the cluster of conditions that so often travels with obesity

Here's why this matters beyond the headline. Kidney disease, heart disease, diabetes, obesity — these aren't separate problems. They're one tangled metabolic mess, and this study is more evidence that treating the metabolic root with a GLP-1 improves all of them at once. That's the same pattern we keep seeing in the research on inflammation, heart outcomes, and liver disease.

And honestly, it matches what we see in clinic. Our patients come in for weight loss — but the wins they report go way past the scale. Blood pressure improving, energy back, joints quieter. The medication is working on the whole system, and the trials keep proving it.

It's a genuinely exciting time in this field. (Original article linked at the bottom, as always.)

-Daryl

Book a FREE consult now <- Click There!

www.pnwmedicalgroup.com

Puyallup: 253-340-2270

Federal Way: 253-363-8877